American Journal of Psychiatry and Neuroscience

| Peer-Reviewed |

Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR)

Received: 29 September 2015    Accepted: 21 October 2015    Published: 30 October 2015
Views:       Downloads:

Share This Article

Abstract

Background: The aim of this study was to assess the medication use in children and adolescents with mental retardation (MR) retrospectively in a cross-sectional study. Method: Between June and December 2013, records of the children and adolescents admitted by our policlinic were retrospectively evaluated and those who had MR diagnosis were analyzed. Results: Male sex was found as statistically related to the presence of psychiatric comorbidity and the pervasive developmental disorders (PDD). At least one medical diagnosis accompanying with MR was found in 49.7% (n=781) of all patients. 79.6% (n=1252) of all patients did not use any medication, 16.7% (n=262) of all sample were using one medication agent, 3.5% (n=55) of patients were using combined pharmacotherapy. The predictors of psychotropic medication were the following: the presence of comorbid any of psychiatric disorders, having attention deficit hyperactivity disorder (ADHD), having conduct disorders (CD) and having anxiety disorders. Conclusions and Recommendations: This study has a descriptive nature of the children with MR admitted to the child psychiatry department. It was noticed that psychotropic agent use is preferable if there is a comorbid situation in mental retardation. There is a need for further studies with prospectively planned, multi-central with larger sampling in our country to draw up a way of health policies related to the children with MR.

DOI 10.11648/j.ajpn.20150306.13
Published in American Journal of Psychiatry and Neuroscience (Volume 3, Issue 6, November 2015)
Page(s) 111-115
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Mental Retardation, Children, Adolescent, Psychotrop Use, Comorbidity

References
[1] Luckasson R, Borthwick-Duffy S, Buntinx WH et al. “Mental retardation: Definition, classification, and systems of supports”. American Association on Mental Retardation, 2002.
[2] John NJ. “Mental Retardation”. In: Stern TA, Rosenbaum JF, Fava M, Biederman J & Rauch SL (eds) Massachusetts General Hospital Comprehensive Clinical Psychiatry, Elsevier Health Sciences, 2008; 247-54.
[3] Kilic BG, Aysel A. “Psychopathology in children with medical diseases comorbid with”. Turk J Child Adolesc Ment Health 2008; 12(3): 115-20.
[4] Szymanski L, King BH. “Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders”. J Am Acad Child Adolesc Psychiatry 1999; 38 (12): 5S-31S.
[5] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR) 4th ed. American Psychiatric Association, Washington, DC, 2000.
[6] Chapman DA., Scott KG, Stanton-Chapman TL. “Public health approach to the study of mental retardation”. Journal Information 2008; 113 (2): 102-16.
[7] Tang KM, Chen TY, Lau VW, Wu MM. “Clinical profile of young children with mental retardation and developmental delay in Hong Kong”. Hong Kong Medical Journal 2008; 14 (2): 97.
[8] Aktepe E, Sonmez Y. “Comorbid psychiatric and non-psychiatric diagnosis of children with Mental Retardation admitted by a university hospital”. New Symposium Journal 2012; 50: 67-75.
[9] Guzel E. “The features of children who admitted to a child psychiatry department and diagnosed by Mental Retardation”. Speciality Thesis. Adana, 2009.
[10] Aicardi J, Bax M, Gillberg C, Ogier H. Diseases of the nervous system in childhood (Vol. 559), Mac Keith Press, London, 1998; 822-25.
[11] Canitano R. “Epilepsy in autism spectrum disorders”. Eur Child Adolesc Psychiatry 2007; 16: 61-66.
[12] Sunmonu TA, Komolafe MA. “Intellectual impairment in patients with epilepsy in Nigeria”. Acta Neurol Scand 2008; 118: 395-401.
[13] Ulovec Z, Čivljak M, Szirovicza L. “Prevalence and significance of minor anomalies in children with impaired development”. Acta Paediatr 2004; 93(6): 836-840.
[14] Einfeld SL, Tonge BJ. “Population prevalence of psychopathology in children and adolescents with intellectual disability: II epidemiological findings”. J Intellect Disabil Res 1996; 40(2): 99-109.
[15] Emerson E, Hatton C. “Mental health of children and adolescents with intellectual disabilities in Britain”. Br J Psychiatry 2007; 191(6): 493-99.
[16] Rojahn JL, Matson JA. “Relationships between psychiatric conditions and behavior problems among adults with mental retardation”. Am J Ment Retard 2004; 109: 21-33.
[17] Holden B, Gitlesen JP. “Psychotropic medication in adults with mental retardation: prevalence, and prescription practices”. Res Dev Disabil 2004; 25(6): 509-21.
[18] Bouras N, Cowley A, Holt G, Newton JT, Sturmey P. “Referral trends of people with intellectual disabilities and psychiatric disorders”. J Intellect Disabil Res 2003; 47: 439-46.
[19] Frighi V, Stephenson MT, Morovat A, Jolley IE, Trivella M, Dudley CA et al. “Safety of antipsychotics in people with intellectual disability”. Br J Psychiatry 2011; 199 (4): 289-95.
[20] Pearson DA, Lane DM, Santos CW, Casat CD, Jerger SW, Loveland KA et al. “Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response”. J Am Acad Child Adolesc Psychiatry 2004; 43(6): 686-98.
[21] Scheifes A, de Jong D, Stolker JJ, Nijman HL, Egberts TC, Heerdink ER. “Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability”. Res Dev Disabil 2013; 34 (10): 3159-67.
Author Information
  • Child Psychiatry, Ankara Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

  • Child Psychiatry, Ankara Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

  • Child Psychiatry, Ankara Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

  • Child Psychiatry, Ankara Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

  • Child Psychiatry, Ankara Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

Cite This Article
  • APA Style

    Seyhan Temtek, Ozden Sukran Uneri, Zeynep Goker, Gulser Dinc, Ozlem Hekim. (2015). Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR). American Journal of Psychiatry and Neuroscience, 3(6), 111-115. https://doi.org/10.11648/j.ajpn.20150306.13

    Copy | Download

    ACS Style

    Seyhan Temtek; Ozden Sukran Uneri; Zeynep Goker; Gulser Dinc; Ozlem Hekim. Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR). Am. J. Psychiatry Neurosci. 2015, 3(6), 111-115. doi: 10.11648/j.ajpn.20150306.13

    Copy | Download

    AMA Style

    Seyhan Temtek, Ozden Sukran Uneri, Zeynep Goker, Gulser Dinc, Ozlem Hekim. Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR). Am J Psychiatry Neurosci. 2015;3(6):111-115. doi: 10.11648/j.ajpn.20150306.13

    Copy | Download

  • @article{10.11648/j.ajpn.20150306.13,
      author = {Seyhan Temtek and Ozden Sukran Uneri and Zeynep Goker and Gulser Dinc and Ozlem Hekim},
      title = {Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR)},
      journal = {American Journal of Psychiatry and Neuroscience},
      volume = {3},
      number = {6},
      pages = {111-115},
      doi = {10.11648/j.ajpn.20150306.13},
      url = {https://doi.org/10.11648/j.ajpn.20150306.13},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajpn.20150306.13},
      abstract = {Background: The aim of this study was to assess the medication use in children and adolescents with mental retardation (MR) retrospectively in a cross-sectional study. Method: Between June and December 2013, records of the children and adolescents admitted by our policlinic were retrospectively evaluated and those who had MR diagnosis were analyzed. Results: Male sex was found as statistically related to the presence of psychiatric comorbidity and the pervasive developmental disorders (PDD). At least one medical diagnosis accompanying with MR was found in 49.7% (n=781) of all patients. 79.6% (n=1252) of all patients did not use any medication, 16.7% (n=262) of all sample were using one medication agent, 3.5% (n=55) of patients were using combined pharmacotherapy. The predictors of psychotropic medication were the following: the presence of comorbid any of psychiatric disorders, having attention deficit hyperactivity disorder (ADHD), having conduct disorders (CD) and having anxiety disorders. Conclusions and Recommendations: This study has a descriptive nature of the children with MR admitted to the child psychiatry department. It was noticed that psychotropic agent use is preferable if there is a comorbid situation in mental retardation. There is a need for further studies with prospectively planned, multi-central with larger sampling in our country to draw up a way of health policies related to the children with MR.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Psychotropic Medication Use in Children and Adolescents with Mental Retardation (MR)
    AU  - Seyhan Temtek
    AU  - Ozden Sukran Uneri
    AU  - Zeynep Goker
    AU  - Gulser Dinc
    AU  - Ozlem Hekim
    Y1  - 2015/10/30
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ajpn.20150306.13
    DO  - 10.11648/j.ajpn.20150306.13
    T2  - American Journal of Psychiatry and Neuroscience
    JF  - American Journal of Psychiatry and Neuroscience
    JO  - American Journal of Psychiatry and Neuroscience
    SP  - 111
    EP  - 115
    PB  - Science Publishing Group
    SN  - 2330-426X
    UR  - https://doi.org/10.11648/j.ajpn.20150306.13
    AB  - Background: The aim of this study was to assess the medication use in children and adolescents with mental retardation (MR) retrospectively in a cross-sectional study. Method: Between June and December 2013, records of the children and adolescents admitted by our policlinic were retrospectively evaluated and those who had MR diagnosis were analyzed. Results: Male sex was found as statistically related to the presence of psychiatric comorbidity and the pervasive developmental disorders (PDD). At least one medical diagnosis accompanying with MR was found in 49.7% (n=781) of all patients. 79.6% (n=1252) of all patients did not use any medication, 16.7% (n=262) of all sample were using one medication agent, 3.5% (n=55) of patients were using combined pharmacotherapy. The predictors of psychotropic medication were the following: the presence of comorbid any of psychiatric disorders, having attention deficit hyperactivity disorder (ADHD), having conduct disorders (CD) and having anxiety disorders. Conclusions and Recommendations: This study has a descriptive nature of the children with MR admitted to the child psychiatry department. It was noticed that psychotropic agent use is preferable if there is a comorbid situation in mental retardation. There is a need for further studies with prospectively planned, multi-central with larger sampling in our country to draw up a way of health policies related to the children with MR.
    VL  - 3
    IS  - 6
    ER  - 

    Copy | Download

  • Sections